Natixis’s Cardiol Therapeutics CRDL Stock Holding History

Natixis’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-25,000	Closed	-$22.4K	–	1010
2023 Q2	$22.4K	Buy	+25,000	New	+$16.5K	﹤0.01%	886

Other funds holding CRDL

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

AXS Investments Port Chester, New York $248M AUM 15.95% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

LNWTC

Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return

MOS

MGO One Seven Beachwood, Ohio $4.98B AUM 22.72% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Natixis's CRDL Position: Q3 2023 in Review

Natixis sold out of Cardiol Therapeutics (CRDL) in Q3 2023, closing a stake of 25,000 shares — an estimated $22.4K sold.

Natixis first reported a position in CRDL in Q2 2023 and held it in 1 quarter. The position peaked at $22.4K in Q2 2023. 35 funds tracked by Wall St. Rank hold CRDL as of Q3 2023.

Natixis reported no remaining Cardiol Therapeutics position as of Q3 2023 after selling out during the quarter.
Natixis sold 25,000 Cardiol Therapeutics shares in Q3 2023, an estimated $22.4K.
Natixis first reported a position in Cardiol Therapeutics in Q2 2023 and held it in 1 quarter.
Natixis's Cardiol Therapeutics position peaked at $22.4K in Q2 2023.
35 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2023.

Based on Natixis's 13F filing for Q3 2023, filed 14 Nov 2023.